Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development
Retrieved on:
Wednesday, November 17, 2021
Stanford University School of Medicine, Patient, Senior, Virginia, Degenerative disease, Environmental engineering, M281, Disclosure, Biophysical environment, Security (finance), Lists of diseases, Safety, Risk, Industry, Scripps Institution of Oceanography, BANK, CD32B, DART, Company, News, Virginia Mason Medical Center, Bristol Myers Squibb, Clinical trial, University, Regulation, U.S. Securities and Exchange Commission, Ocean, Lupus, University of Washington Department of Bioengineering, COVID-19, California Institute for Quantitative Biosciences, California, Nasdaq, Twitter, CD79B, Drug, Health, Bio, ANCA, Michigan State University, Assistant, RED, Harvard Medical School, Education, Growth, ZymoGenetics, Translation, Pharmaceutical industry
RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development.
Key Points:
- RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development.
- Dr. Hillson was most recently Senior Vice President, Clinical Development at Alpine Immune Sciences.
- Dr. Hillson also served as Senior Vice Presidentof Clinical and Translational Research at ChemoCentryx.
- As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products.